Trelstar

Links shared publicly online about this topic

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

news-medical.net — “Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.View full resource at news-medical.net

  • View Related
  • Share

Most Recently Shared on March 12, 2010 at 4:58 am By:

NewsMedical News-Medical.Net Health News

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer: Watson Pharmace... http://bit.ly/9DZlKM

2 years ago...

Trelstar 22.5mg approved for palliative treatment of prostate cancer - MPR

empr.com — “The FDA has approved Trelstar 22.5mg (triptorelin pamoate for injectable suspension, from Watson) for the palliative treatment of advanced prostate cancer.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on March 11, 2010 at 11:15 pm By:

eMPR MPR Medical Publisher

MPR News: Trelstar 22.5mg approved for palliative treatment of prostate cancer: The FDA has approved Trelstar 22.... http://bit.ly/a9jpzz

2 years ago...

PR-USA.net - FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for

pr-usa.net — “PR-USA.netView full resource at pr-usa.net

  • View Related
  • Share

Most Recently Shared on March 15, 2010 at 4:34 pm By:

RoswellPark Roswell Park Hospital

FDA approves a new 2x-yearly formulation of TRELSTAR®, a palliative treatment of advanced prostate cancer http://bit.ly/d90mzN

2 years ago...

FDA orders new warnings on prostate cancer drugs | Reuters

reuters.com — “WASHINGTON (Reuters) - Certain hormone treatments for prostate cancer must carry new warnings about an increased risk of diabetes and heart problems, the U.S. Food and Drug Administration said on Wednesday. TheView full resource at reuters.com

  • View Related
  • Share

Most Recently Shared on October 20, 2010 at 10:27 pm By:

FDA orders new warnings on prostate cancer drugs

health.yahoo.net — “Certain hormone treatments for prostate cancer must carry new warnings about an increased risk of diabetes and heart problems, the U.S. Food and Drug Administration said on Wednesday.View full resource at health.yahoo.net

  • View Related
  • Share

Most Recently Shared on October 20, 2010 at 10:07 pm By:

JennyBizRN Jennifer Ann Grisso Nurse and Active Health Library

FDA orders new warnings on prostate cancer drugs: Certain hormone treatments for prostate cancer must carry new wa... http://bit.ly/czzEGz

2 years ago...

FDA orders new warnings on prostate cancer drugs | Reuters

reuters.com — “WASHINGTON (Reuters) - Certain hormone treatments for prostate cancer must carry new warnings about an increased risk of diabetes and heart problems, the U.S. Food and Drug Administration said on Wednesday. TheView full resource at reuters.com

  • View Related
  • Share

Most Recently Shared on October 20, 2010 at 10:01 pm By:

Reuters_Health Reuters Health Health News

FDA orders new warnings on prostate cancer drugs http://dlvr.it/7JNdQ

2 years ago...

FDA Drug Safety Communication: Ongoing Safety Review of GnRH Agonists and Possible Increased Risk of Diabetes and Certain Cardiovascular Diseases - Drugs.com MedNews

drugs.com — “05-03-2010 The U.S. Food and Drug Administration (FDA) is evaluating whether Gonadotropin-Releasing Hormone (GnRH) Agonists may increase the risk of diabetes anView full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on May 4, 2010 at 11:02 pm By:

drugscom Drugs.com Health Site

FDA: Ongoing Safety Review of GnRH Agonists - http://bit.ly/bDyEi7

2 years ago...

Watson Pharmaceuticals, Inc. | Investors |

ir.watson.com — “Watson Pharmaceuticals, Inc. | Investors |View full resource at ir.watson.com

  • View Related
  • Share

Most Recently Shared on July 14, 2009 at 2:09 pm By:

eyeonfda eyeonfda Pharma and Health Lawyer

Watson Gets a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) http://bit.ly/aAiwq

3 years ago...

The Top 3 resources shared on this topic. More resources.

Key stats and trends about this topic

Featuring the top 3 experts for this topic

  • NewsMedical

    News-Medical.Net

    Medical News from Around the World

    View Profile

  • eMPR

    MPR

    eMPR.com provides up-to-date, concise drug information at the point-of-care.

    View Profile

  • RoswellPark

    Roswell Park

    World's first & only Upstate New York Comprehensive Cancer Center. One Mission: understand, prevent and cure cancer. Follow also at Facebook.com/RoswellPark

    View Profile

Advertisement

Share via Email

Share this WisdomCard with others by embedding on your site or blog.

300x260

425x300

560x390